Technology | Nuclear Imaging | January 16, 2019

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry

MIM SurePlan MRT provides quantitative SPECT reconstruction and voxel-based absorbed dose calculation for molecular radiotherapy

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry

January 16, 2019 — MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy (MRT) dosimetry.

MRT is an effective form of therapy that uses radiopharmaceuticals such as Lutathera (Lu-177 DOTATATE) and Azedra (I-131 iobenguane) to target tumors based on certain receptors that these tumors express.

Until now, there has not been an effective way to measure the absorbed dose from MRT for an individual patient. This is due to a lack of access to quantitative single photon emission computed tomography (SPECT) images and tools for calculating dose on the patient's own anatomy. MIM SurePlan MRT provides both quantitative SPECT reconstruction and voxel-based absorbed dose calculation by utilizing the patient's own images, allowing for personalized dosimetry measurements.

MIM SurePlan MRT provides timesaving tools for organ and tumor segmentation, deformable registration and voxel-based dosimetry for molecular radiotherapy. Other features of MIM SurePlan MRT include multi-tracer theranostics support, quantitative SPECT and planar corrections, and dosimetry reporting tools.

MIM Software will demonstrate MIM SurePlan MRT at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Mid-Winter Meeting, Jan. 18-19 in Palm Springs, Calif.

For more information: www.mimsoftware.com

Related Content

First GammaTile Therapy Case Completed in Arizona
News | Radiation Therapy | August 19, 2019
HonorHealth Scottsdale Osborn Medical Center is the first hospital in Arizona to begin offering GammaTile Therapy, a...
Drug Accelerates Blood System's Recovery After Radiation, Chemotherapy

Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communications

News | Radiation Therapy | August 16, 2019
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem...
Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Catalyst PT image courtesy of C-RAD

News | Patient Positioning Radiation Therapy | August 15, 2019
Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton...
United Imaging Announces First U.S. Clinical Installation of uExplorer Total-body PET/CT
News | PET-CT | August 15, 2019
United Imaging announced that its uExplorer total-body positron emission tomography/computed tomography (PET/CT) system...
First Patient Enrolled in World's Largest Brain Cancer Clinical Trial
News | Radiation Therapy | August 15, 2019
Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive...
Efficacy of Isoray's Cesium Blu Showcased in Recent Studies
News | Brachytherapy Systems | August 14, 2019
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica
MD Anderson to Expand Proton Therapy Center

The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.

News | Proton Therapy | August 08, 2019
The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a...
Qfix kVue One Proton Couch Top Validated by Mevion Medical Systems
News | Patient Positioning Radiation Therapy | August 07, 2019
Qfix and Mevion Medical Systems announced that a special version of the kVue One Proton couch top is now both validated...
IBA Signs Contract to Install Proton Therapy Center in Kansas
News | Proton Therapy | August 06, 2019
IBA (Ion Beam Applications S.A.) recently signed a contract and received the first payment for a Proteus One solution...